• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Medius Holdings (TSE:3154) Stock Price Reflects Revenue Stability And Profit Erosion

    Simply Wall St·08/13/2026 08:38:38
    Listen to the news

    Medius Holdings stock closed at ¥779 today after a flat week and a weak three month stretch, yet the real story is inside the income statement. The headline is a profit squeeze. Full year revenue sat in the ¥74,000 million range this quarter, but net income swung to a loss and the trailing net margin over the last year sat at only 0.3%. Investors are treating Medius as a premium healthcare stock with a P/E of 18.3x while multi year earnings have been declining. That tension between price and shrinking profitability is what matters most in this earnings print.

    Is Medius Holdings trading at a premium that current earnings and a thin 0.3% net margin cannot justify, or is the market already pricing in a turnaround story? Compare the market price against detailed cash flow and peer multiples in our valuation analysis for Medius Holdings.

    FY 2026 Earnings Summary

    • Revenue (Q4 FY 2026 vs Q4 FY 2025): ¥74,656.345 million vs. ¥69,177.575 million (higher quarterly revenue year on year)
    • Net Income/Loss (Q4 FY 2026 vs Q4 FY 2025): loss of ¥338.171 million vs. profit of ¥4.247 million (turned to a quarterly loss year on year)
    • Basic EPS (Q4 FY 2026 vs Q4 FY 2025): loss of ¥15.21 per share vs. profit of ¥0.19 per share (moved from a small profit to a loss per share)
    • Net Profit Margin (TTM FY 2026 vs prior TTM): 0.3% vs. 0.5% (margin weakened on a trailing twelve month basis)

    Prefer clear visuals instead of scrolling through dense earnings tables and tiny margin figures for Medius Holdings? Get a full picture of the stock with an at a glance view of its valuation in the company report for Medius Holdings.

    TSE:3154 Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026
    TSE:3154 Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026

    Revenue Resilience Supports Medius Holdings Bulls

    For investors leaning toward the defensive healthcare story, Medius Holdings still offers some support. Full year revenue in Q4 FY 2026 sat at ¥74,656.345 million compared with ¥69,177.575 million in Q4 FY 2025. That fits a picture of ongoing demand for medical consumables and services. The share price has been broadly flat over 30 days and only slightly weaker over 7 days, which suggests no sharp loss of confidence. For a business often viewed as a healthcare infrastructure supplier, that combination of steady sales and contained share price moves matters.

    Profit Squeeze Keeps Bearish Arguments Alive

    The weak side of the story is profitability. Medius Holdings moved from a small profit of ¥4.247 million in Q4 FY 2025 to a loss of ¥338.171 million in Q4 FY 2026. Basic EPS followed the same direction, shifting from a ¥0.19 profit per share to a ¥15.21 loss per share. A trailing net margin of 0.3%, down from 0.5%, underlines how thin the cushion has become. With the stock down about 8% over 90 days, the market appears to be reacting more to this profit squeeze than to revenue stability.

    After a 15.7% annual earnings decline and thin 0.3% margins, you might ask if this profit squeeze is temporary or structural. Review our risk analysis for Medius Holdings which shows 4 important warning signs to see whether these visible issues sit on top of deeper balance sheet and cash flow warning signs.

    Take Control Of Your Next Move

    If the mix of resilient revenue and squeezed margins at Medius Holdings has caught your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch for a better entry point. Once you own Medius Holdings or any other stock, use the Portfolio Command Center to cut through noise and focus on the key developments that matter to your holdings. For a broader view on what other investors are seeing, tap into the Community and compare your thesis with crowd insights. This combination helps you surface hidden catalysts and risks early so you can stay a step ahead of the market.

    Seeking Alternatives Beyond Medius Holdings?

    Fresh ideas can move before you even notice the breakout starting. Scan under the radar stocks while the data is still sharp and the crowd is late. Act now.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.